BACKGROUND: There is limited insight into the current disease burden and everyday clinical management of moderate-to- severe AD in Poland, Czechia, Russia, and Turkiye. Therefore, this study aimed to get information-driven insights regarding the current disease burden and clinical management of patients with moderate-to-severe AD with common and differentiating aspects of the patient journey and establish a consensus. METHODS: In this modified 2-round Delphi panel, 133 questions were asked in total to 27 dermatologists. A consensus was achieved when 70% of the panel members strongly agreed or agreed (or strongly disagreed or disagreed) with an item. Statements with <40% agreement dropped from the Delphi rounds and were not repeated. RESULTS: The results state that AD has a significant impact on the quality of life for both patients and their families with social and economic consequences in these countries. While there were significant dissimilarities regarding the current treatment approach by preference order and treatment duration among participants, there was also a high percentage of consensus on literature and guideline-based statements. Current topical therapies and the immune response modifiers were not found to be sufficient by panelists to cover the therapeutic needs of patients with moderate-to-severe AD. Moreover, panelists highlighted the significant burden of adverse events with the off-label use of currently available immunosuppressants. CONCLUSIONS: These results underlined that there is a significant disease burden with an unmet treatment need for patients with moderate-to-severe AD in Poland, Czechia, Russia, and Turkiye.

Centre of Allergy and Immunology Clinical State Hospital 52 Moscow Ministry of Healthcare Moscow Russia

Department of Dermatology 1 M Sechenov Moscow Medical University Moscow Russia

Department of Dermatology AGEL Prague Czechia

Department of Dermatology and Venereology Akdeniz University Antalya Türkiye

Department of Dermatology and Venereology Erciyes University Kayseri Türkiye

Department of Dermatology and Venereology Koç University İstanbul Türkiye

Department of Dermatology and Venerology Cerrahpaşa Medical Faculty Istanbul University Cerrahpaşa İstanbul Türkiye

Department of Dermatology Ege University İzmir Türkiye

Department of Dermatology Federal State Autonomous Institution Scientific Centre of Children's Health of the Ministry of Health of the Russian Federation Moscow Russia

Department of Dermatology Federal State Budgetary Institution of Continuing Professional Education Central State Medical Academy Moscow Russia

Department of Dermatology Hospital in Ústí nad Labem Ústí nad Labem Czechia

Department of Dermatology Marmara University İstanbul Türkiye

Department of Dermatology Medical Research and Educational Center Lomonosov Moscow State University Moscow Russia

Department of Dermatology Medical University of Poznań Poznań Poland

Department of Dermatology Medical University of Warsaw Warsaw Poland

Department of Dermatology Military Institute of Medicine Warsaw Poland

Department of Dermatology University of Rzeszow Rzeszów Poland

Department of Dermatology Venereology and Allergology Medical University of Gdańsk Gdańsk Poland

Department of Dermatovenereology 1st Medical Faculty Charles University Prague Czechia

Department of Dermatovenerology 3rd Faculty of Medicine Charles University of Prague Prague Czechia

Dermatology and Venereology Clinic Medical University Łodź Poland

Istanbul Faculty of Medicine Department of Dermatology and Venereology Istanbul University İstanbul Türkiye

Moscow Scientific and Practical Centre of Dermatovenereology and Cosmetology Moscow Russia

NRC Institute of Immunology FMBA of Russia Moscow Russia

Pfizer İstanbul Türkiye

See more in PubMed

Mortz CG, Andersen KE, Dellgren C, Barington T, Bindslev-Jensen C. Atopic dermatitis from adolescence to adulthood in the TOACS cohort: prevalence, persistence and comorbidities. Allergy. (2015) 70:836–45. 10.1111/all.12619 PubMed DOI

DaVeiga SP. Epidemiology of atopic dermatitis: a review. Allergy Asthma Proc. (2012) 33:227–34. 10.2500/aap.2012.33.3569 PubMed DOI

Flohr C, Mann J. New insights into the epidemiology of childhood atopic dermatitis. Allergy. (2014) 69:3–16. 10.1111/all.12270 PubMed DOI

Harrop J, Chinn S, Verlato G, Olivieri M, Norbäck D, Wjst M, et al. . Eczema, atopy and allergen exposure in adults: a population-based study. Clin Exp Allergy. (2007) 37:526–35. 10.1111/j.1365-2222.2007.02679.x PubMed DOI

Flohr C, Weiland SK, Weinmayr G, Björkstén B, Bråbäck L, Brunekreef B, et al. . The role of atopic sensitization in flexural eczema: findings from the International Study of Asthma and Allergies in Childhood Phase Two. J Allergy Clin Immunol. (2008) 121:141–7. 10.1016/j.jaci.2007.08.066 PubMed DOI

Pesce G, Marcon A, Carosso A, Antonicelli L, Cazzoletti L, Ferrari M, et al. . Adult eczema in Italy: prevalence and associations with environmental factors. J Eur Acad Dermatol Venereol. (2015) 29:1180–7. 10.1111/jdv.12784 PubMed DOI

Theodosiou G, Montgomery S, Metsini A, Dalgard FJ, Svensson Å, Kobyletzki LB. Burden of atopic dermatitis in Swedish adults: a population-based study. Acta Derm Venereol. (2019) 99:964–70. 10.2340/00015555-3257 PubMed DOI

Deckers IA, McLean S, Linssen S, Mommers M, van Schayck CP, Sheikh A, et al. . Investigating international time trends in the incidence and prevalence of atopic eczema 1990-2010: a systematic review of epidemiological studies. PLoS ONE. (2012) 7:e39803. 10.1371/journal.pone.0039803 PubMed DOI PMC

Barbarot S, Auziere S, Gadkari A, Girolomoni G, Puig L, Simpson EL, et al. . Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. (2018) 73:1284–93. 10.1111/all.13401 PubMed DOI

Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, et al. . Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. (2014) 70:338–51. 10.1016/j.jaad.2013.10.010 PubMed DOI PMC

Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. (2015) 66:8–16. 10.1159/000370220 PubMed DOI

Silverberg JI. Public health burden and epidemiology of atopic dermatitis. Dermatol Clin. (2017) 35:283–9. 10.1016/j.det.2017.02.002 PubMed DOI

Bylund S, Kobyletzki LB, Svalstedt M, Svensson Å. Prevalence and incidence of atopic dermatitis: a systematic review. Acta Derm Venereol. (2020) 100:adv00160. 10.2340/00015555-3510 PubMed DOI PMC

Drucker AM. Atopic dermatitis: Burden of illness, quality of life, and associated complications. Aller Asthma Proc. (2017) 38:3–8. 10.2500/aap.2017.38.4005 PubMed DOI

Salvador S, Romero-Pérez D, Encabo-Durán B. Atopic dermatitis in adults: a diagnostic challenge. J Investig Allergol Clin Immunol. (2017) 27:78–88. 10.18176/jiaci.0138 PubMed DOI

Schmitt J, Langan S, Williams HC, European Dermato-Epidemiology Network. What are the best outcome measurements for atopic eczema? A systematic review. J Allergy Clin Immunol. (2007) 120:1389–98. 10.1016/j.jaci.2007.08.011 PubMed DOI

Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. (2001) 10:11–8. 10.1034/j.1600-0625.2001.100102.x PubMed DOI

David Boothe W, Tarbox JA, Tarbox MB. Atopic dermatitis: pathophysiology. Adv Exp Med Biol. (2017) 1027:21–37. 10.1007/978-3-319-64804-0_3 PubMed DOI

Czarnowicki T, Krueger JG, Guttman-Yassky E. Skin barrier and immune dysregulation in atopic dermatitis: an evolving story with important clinical implications. J Allergy Clin Immunol Pract. (2014) 2:371–9. 10.1016/j.jaip.2014.03.006 PubMed DOI

Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, Bergman JN, et al. . Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. (2014) 71:327–49. 10.1016/j.jaad.2014.03.030 PubMed DOI PMC

Ortiz de Frutos FJ, Torrelo A, de Lucas R, González MA, Alomar A, Vera Á et al. Patient perspectives on triggers, adherence to medical recommendations. Dermatology. (2014) 71:327–49. 10.1016/j.ad.2014.01.004 PubMed DOI

Hay RJ, Johns NE, Williams HC, Bollinger IW, Dellavalle RP, Margolis DJ, et al. . The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Investig Dermatol Symp Proc. (2014) 134:1527–34. 10.1038/jid.2013.446 PubMed DOI

Graham B, Regehr G, Wright JG. Delphi as a method to establish consensus for diagnostic criteria. J Clin Epidemiol. (2003) 56:1150–6. 10.1016/S0895-4356(03)00211-7 PubMed DOI

von der Gracht H. Consensus measurement in Delphi studies - review and implications for future quality assurance. Technol Forecast Soc Change. (2012) 79:1525–36. 10.1016/j.techfore.2012.04.013 DOI

Rowe G, Wright G. The Delphi technique as a forecasting tool: issues and analysis. Int J Forecast. (1999) 15:353–75. 10.1016/S0169-2070(99)00018-7 DOI

Strasser A. Delphi method variants in information systems research: taxonomy development and application. Electr J Bus Res Methods. (2017) 15:120–133.

Wollenberg A, Christen-Zäch S, Taieb A, Paul C, Thyssen JP, de Bruin-Weller M, et al. . ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. (2020) 34:2717–44. 10.1111/jdv.16892 PubMed DOI

Lio P, Wollenberg A, Thyssen J, Pierce E, Rueda M, DeLozier A, et al. . Impact of atopic dermatitis lesion location on quality of life in adult patients in a real-world study. Dermatol Ther. (2020) 10:663–72. 10.36849/JDD.2020.5422 PubMed DOI

Ribero S, Puglisi B, Giura MT, Viola R, Siliquini N, Quaglino P, et al. . Head and neck severity index is associated with a significant worsening of quality of life in atopic dermatitis patients. J Eur Acad Dermatol Venereol. (2021) 35:1335–41. 10.1111/exd.14368 PubMed DOI

Zhang J, Loman L, Oldhoff JM, Schuttelaar M. Beyond anxiety and depression: loneliness and psychiatric disorders in adults with atopic dermatitis. J Invest Dermatol. (2023) 143:688–94. 10.2340/actadv.v103.9378 PubMed DOI PMC

Luger T, Romero W, Gruben D, Smith TW, Cha A, Neary M. Clinical and humanistic burden of atopic dermatitis in Europe: analyses of the national health and wellness survey. J Eur Acad Dermatol Venereol. (2022) 36:56–65. 10.1007/s13555-022-00700-6 PubMed DOI PMC

Arima K, Gupta S, Gadkari A, Hiragun T, Kono T, Katayama I, et al. . Burden of atopic dermatitis in Japanese adults: analysis of data from the 2013 National Health and Wellness Survey. J Dermatol. (2018) 45:281–8. 10.1111/1346-8138.14218 PubMed DOI PMC

Frings V, Böer-Auer A, Breuer K. Histomorphology and immunophenotype of eczematous skin lesions revisited—skin biopsies are not reliable in differentiating allergic contact dermatitis, irritant contact dermatitis, and atopic dermatitis. J Cutan Pathol. (2018) 47:519–27. 10.1097/DAD.0000000000000842 PubMed DOI

Lee S. Various diagnostic criteria for atopic dermatitis (AD): a proposal of Reliable Estimation of Atopic Dermatitis in Childhood (REACH) criteria, a novel questionnaire-based diagnostic tool for AD. J Dermatol. (2016) 43:359–65. 10.1111/1346-8138.13264 PubMed DOI

Vakharia P, Chopra R, Silverberg J. Systematic Review of Diagnostic Criteria Used in Atopic Dermatitis Randomized Controlled Trials. Am J Clin Dermatol. (2018) 19:15–26. 10.1007/s40257-017-0299-4 PubMed DOI

Flohr C. Atopic dermatitis diagnostic criteria and outcome measures for clinical trials: still a mess. J Invest Dermatol. (2011) 131:557–9. 10.1038/jid.2010.369 PubMed DOI

Gooderham M, Bissonnette R, Grewal PS, Lansang P, Papp K, Hong C. Approach to the assessment and management of adult patients with atopic dermatitis: a consensus document. Section II: tools for assessing the severity of atopic dermatitis. J Cutaneous Med Surg. (2018) 22:22S−7S. 10.1177/1203475418803628 PubMed DOI

Rehal B, Armstrong A. Health outcome measures in atopic dermatitis: a systematic review of trends in disease severity and quality-of-life instruments 1985–2010. PLoS ONE. (2011) 6:e17520. 10.1371/journal.pone.0017520 PubMed DOI PMC

Eichenfield L, Boguniewicz M, Simpson E, Russell JJ, Block J, Feldman S, et al. . Translating atopic dermatitis management guidelines into practice for primary care providers. Pediatrics. (2015) 136:554–65. 10.1542/peds.2014-3678 PubMed DOI

Mohan GC, Lio P. Comparison of dermatology and allergy guidelines for atopic dermatitis management. JAMA Dermatol. (2015) 151:1009–13. 10.1001/jamadermatol.2015.0250 PubMed DOI

Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. . Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. (2018) 32:657–82. 10.1111/jdv.14891 PubMed DOI

Siegfried E, Jaworski JC, Kaiser J, Hebert A. Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC Pediatr. (2016) 16:75. 10.1186/s12887-016-0607-9 PubMed DOI PMC

Patrizi A, Raone B, Ravaioli GM. Management of atopic dermatitis: safety and efficacy of phototherapy. Clin Cosmet Invest Dermatol. (2015) 8:511–520. 10.2147/CCID.S87987 PubMed DOI PMC

Pavlovsky M, Baum S, Shpiro D, Pavlovsky L, Pavlotsky F. Narrow band UVB: is it effective and safe for paediatric psoriasis and atopic dermatitis? J Eur Acad Dermatol Venereol. (2011) 25:727–9. 10.1111/j.1468-3083.2010.03832.x PubMed DOI

Kemény L, Varga E, Novák Z. Advances in phototherapy for psoriasis and atopic dermatitis. Expert Opin Pharmacother. (2019) 21:407–19. 10.1080/1744666X.2020.1672537 PubMed DOI

Newsom M, Bashyam AM, Balogh EA, Feldman SR, Strowd LC. New and emerging systemic treatments for atopic dermatitis. Drugs. (2020) 80:1041–52. 10.1007/s40265-020-01335-7 PubMed DOI PMC

Wan H, Jia H, Xia T, Zhang D. Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: a network meta-analysis. Dermatol Ther. (2022) 35:e15636. 10.1111/dth.15636 PubMed DOI PMC

Drucker AM, Morra DE, Prieto-Merino D, Ellis AG, Yiu ZZ, Rochwerg B, et al. . Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis. JAMA Dermatol. (2022) 158:523–32. 10.1001/jamadermatol.2022.0455 PubMed DOI PMC

Ricci G, Dondi A, Patrizi A, Masi M. Systemic therapy of atopic dermatitis in children. Drugs. (2009) 69:297–306. 10.2165/00003495-200969030-00005 PubMed DOI